1. Home
  2. SDHY vs SAGE Comparison

SDHY vs SAGE Comparison

Compare SDHY & SAGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SDHY
  • SAGE
  • Stock Information
  • Founded
  • SDHY 2020
  • SAGE 2010
  • Country
  • SDHY United States
  • SAGE United States
  • Employees
  • SDHY N/A
  • SAGE N/A
  • Industry
  • SDHY Finance/Investors Services
  • SAGE Biotechnology: Pharmaceutical Preparations
  • Sector
  • SDHY Finance
  • SAGE Health Care
  • Exchange
  • SDHY Nasdaq
  • SAGE Nasdaq
  • Market Cap
  • SDHY 396.5M
  • SAGE 462.2M
  • IPO Year
  • SDHY N/A
  • SAGE 2014
  • Fundamental
  • Price
  • SDHY $16.47
  • SAGE $5.10
  • Analyst Decision
  • SDHY
  • SAGE Hold
  • Analyst Count
  • SDHY 0
  • SAGE 20
  • Target Price
  • SDHY N/A
  • SAGE $12.89
  • AVG Volume (30 Days)
  • SDHY 94.0K
  • SAGE 822.5K
  • Earning Date
  • SDHY 01-01-0001
  • SAGE 10-29-2024
  • Dividend Yield
  • SDHY 8.46%
  • SAGE N/A
  • EPS Growth
  • SDHY N/A
  • SAGE N/A
  • EPS
  • SDHY 1.07
  • SAGE N/A
  • Revenue
  • SDHY N/A
  • SAGE $106,399,000.00
  • Revenue This Year
  • SDHY N/A
  • SAGE N/A
  • Revenue Next Year
  • SDHY N/A
  • SAGE $118.26
  • P/E Ratio
  • SDHY $14.31
  • SAGE N/A
  • Revenue Growth
  • SDHY N/A
  • SAGE 837.60
  • 52 Week Low
  • SDHY $13.93
  • SAGE $5.03
  • 52 Week High
  • SDHY $15.50
  • SAGE $28.26
  • Technical
  • Relative Strength Index (RSI)
  • SDHY 44.35
  • SAGE 28.88
  • Support Level
  • SDHY $16.41
  • SAGE $5.86
  • Resistance Level
  • SDHY $16.95
  • SAGE $5.87
  • Average True Range (ATR)
  • SDHY 0.17
  • SAGE 0.51
  • MACD
  • SDHY -0.02
  • SAGE -0.14
  • Stochastic Oscillator
  • SDHY 14.29
  • SAGE 1.91

About SDHY PGIM Short Duration High Yield Opportunities Fund

PGIM Short Duration High Yield Opportunities is a closed-end management investment company. The fund's investment objective is to provide total return, through a combination of current income and capital appreciation. Its seeks to achieve its objective by investing in a diversified portfolio of high yield fixed income instruments.

About SAGE Sage Therapeutics Inc.

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.

Share on Social Networks: